Kevin Schroeder, MD
Nephrology · Columbus, OHNPI 1982662078
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,266 of the $1,501 with a category attached, or 84.3%. It is spread thinly across 30 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $444 and has fallen 68.4% since, to $140 in 2025.
Across 70 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$310
- Jazz Pharmaceuticals Inc.$207
- Fresenius USA Marketing, Inc.$87
- Bard Peripheral Vascular, Inc.$86
- Akebia Therapeutics Inc$78
- Novartis$62
- plus $671 from 24 others
Across 5 payments — averaging $103,298 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$486K
- Biogen$31K
What the payments were for
- Travel & lodging$18512%
- Food & beverage$1,26684%
- Education$503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 7 | $310 |
| Jazz Pharmaceuticals Inc. | 2 | $207 |
| Fresenius USA Marketing, Inc. | 6 | $87 |
| Bard Peripheral Vascular, Inc. | 1 | $86 |
| Akebia Therapeutics Inc | 4 | $78 |
| Novartis | 3 | $62 |
| Novo Nordisk | 3 | $57 |
| Bayer | 2 | $54 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Amgen(2 entities) | 3 | $51 |
| Baxter Healthcare | 2 | $38 |
| Ardelyx, Inc. | 2 | $38 |
| Travere Therapeutics, Inc. | 13 | $38 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Mannkind Corporation | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Nxstage Medical, Inc. | 1 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $18 |
| Sanofi | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Aurinia Pharma U.S., Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$111
How this compares
$1,501 in reported general payments places this provider in the 55th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZortressEverolimus | 12 | $60,038 |
| VelphoroSucroferric Oxyhydroxide | 21 | $45,861 |
| FarxigaDapagliflozin Propanediol | 33 | $21,859 |
| ProsolParenteral Amino Acid 20% No.1 | 79 | $10,479 |
| Cinacalcet Hcl | 19 | $9,892 |
| Nifedipine ErNifedipine | 107 | $3,343 |
| Sevelamer Carbonate | 27 | $3,209 |
| Febuxostat | 12 | $2,175 |
| Losartan Potassium | 140 | $1,713 |
| Calcium Acetate | 16 | $1,665 |
| Mycophenolate Mofetil | 21 | $1,509 |
| Torsemide | 42 | $1,476 |
| Hydralazine Hcl | 62 | $1,156 |
| Furosemide | 186 | $1,111 |
| Carvedilol | 127 | $1,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisZortress | $62 | $60,03812 claims |
| Fresenius USA Marketing, Inc.Velphoro | $87 | $45,86121 claims |
| AstraZenecaFarxiga | $310 | $21,85933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 nephrology providers in Ohio.
Other nephrology in Columbus
- Brad RovinColumbus$379K
- Samir ParikhColumbus$145K
- Isabelle AyoubColumbus$116K
- Anil AgarwalColumbus$99K
- Karim AttiaColumbus$43K
- Rima KangColumbus$28K
- Salem AlmaaniColumbus$21K
- Todd PesaventoColumbus$20K
- Naveen SingriColumbus$11K
- Jessica GrecoColumbus$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.